Health Canada proposes new opioid marketing restrictions
Health Canada of Ottawa has proposed new additional restrictions on the marketing of opioids. The new proposals will restrict the marketing and advertising of Class B opioid products to health care professionals. Promotional materials about these drugs, including print and electronic ads and pamphlets, must be limited to statements that have been authorized by Health Canada. These statements would have to be presented verbatim and would convey the benefits and risks of opioids. The proposals are expected to be finalized in April and would go into effect by June.
“I am deeply concerned by the ongoing opioid crisis, which is affecting Canadians from all walks of life,” said Minister of Health Ginette Petitpas Taylor. “I recognize that advertising can influence the prescribing practices of health care professionals. Today’s announcement will help us to ensure that health professionals are getting only factual information about these products, so that they can provide the best possible support to their patients.”